(Q37815561)

23 August 2017

1 reference

title

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic (English)

1 reference

23 August 2017

0 references

L Citrome

1

0 references

language of work or name

1 reference

3 December 2010

1 reference

International Journal of Clinical Practice

23 August 2017

published in

1 reference

23 August 2017

volume

65

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

189-210

1 reference

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Lurasidone: a new drug in development for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Show me the evidence: using number needed to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Compelling or irrelevant? Using number needed to treat can help decide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Size of treatment effects and their importance to clinical research and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Using oral ziprasidone effectively: the food effect and dose-response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02587.X

10.1111/J.1742-1241.2010.02587.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference